Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
CNY 1.69
(0.0%)
CNY 1.69
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.82 Billion CNY | -32.83% |
| 2022 | 13.03 Billion CNY | 32.15% |
| 2021 | 9.86 Billion CNY | 87.56% |
| 2020 | 5.26 Billion CNY | -11.87% |
| 2019 | 5.96 Billion CNY | -0.66% |
| 2018 | 6 Billion CNY | 26.84% |
| 2017 | 4.73 Billion CNY | 36.83% |
| 2016 | 3.46 Billion CNY | 20.96% |
| 2015 | 2.86 Billion CNY | 30.97% |
| 2014 | 2.18 Billion CNY | 36.38% |
| 2013 | 1.6 Billion CNY | -7.77% |
| 2012 | 1.73 Billion CNY | -8.54% |
| 2011 | 1.89 Billion CNY | 32.6% |
| 2010 | 1.43 Billion CNY | 69.7% |
| 2009 | 844.37 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.98 Billion CNY | -16.02% |
| 2024 Q3 | 1.95 Billion CNY | -30.83% |
| 2024 Q2 | 2.82 Billion CNY | 41.99% |
| 2023 Q3 | 2.34 Billion CNY | 38.19% |
| 2023 Q4 | 2.36 Billion CNY | 0.98% |
| 2023 FY | 8.75 Billion CNY | -32.83% |
| 2023 Q1 | 2.39 Billion CNY | -5.94% |
| 2023 Q2 | 1.69 Billion CNY | -29.16% |
| 2022 Q2 | 4.39 Billion CNY | 42.34% |
| 2022 FY | 13.03 Billion CNY | 32.15% |
| 2022 Q4 | 2.54 Billion CNY | -15.55% |
| 2022 Q1 | 3.08 Billion CNY | 10.27% |
| 2022 Q3 | 3.01 Billion CNY | -31.38% |
| 2021 Q3 | 3.15 Billion CNY | 39.75% |
| 2021 Q4 | 2.79 Billion CNY | -11.31% |
| 2021 FY | 9.86 Billion CNY | 87.56% |
| 2021 Q1 | 1.65 Billion CNY | 21.08% |
| 2021 Q2 | 2.25 Billion CNY | 36.44% |
| 2020 Q2 | 1.41 Billion CNY | 38.68% |
| 2020 Q3 | 1.45 Billion CNY | 2.24% |
| 2020 Q4 | 1.36 Billion CNY | -5.82% |
| 2020 FY | 5.26 Billion CNY | -11.87% |
| 2020 Q1 | 1.02 Billion CNY | -16.2% |
| 2019 FY | 5.96 Billion CNY | -0.66% |
| 2019 Q4 | 1.22 Billion CNY | -27.61% |
| 2019 Q1 | 1.42 Billion CNY | -1.66% |
| 2019 Q2 | 1.63 Billion CNY | 14.37% |
| 2019 Q3 | 1.68 Billion CNY | 3.33% |
| 2018 Q3 | 1.64 Billion CNY | -6.99% |
| 2018 FY | 6 Billion CNY | 26.84% |
| 2018 Q4 | 1.45 Billion CNY | -11.54% |
| 2018 Q2 | 1.76 Billion CNY | 53.25% |
| 2018 Q1 | 1.15 Billion CNY | -19.62% |
| 2017 Q1 | 928.14 Million CNY | -15.19% |
| 2017 Q2 | 1.1 Billion CNY | 18.53% |
| 2017 Q3 | 1.27 Billion CNY | 16.07% |
| 2017 Q4 | 1.43 Billion CNY | 12.18% |
| 2017 FY | 4.73 Billion CNY | 36.83% |
| 2016 Q2 | 781.21 Million CNY | 16.86% |
| 2016 FY | 3.46 Billion CNY | 20.96% |
| 2016 Q4 | 1.09 Billion CNY | 19.14% |
| 2016 Q1 | 668.48 Million CNY | -20.17% |
| 2016 Q3 | 918.52 Million CNY | 17.58% |
| 2015 Q2 | 870.15 Million CNY | 78.19% |
| 2015 Q4 | 837.36 Million CNY | 25.58% |
| 2015 Q3 | 666.79 Million CNY | -23.37% |
| 2015 Q1 | 488.32 Million CNY | -33.27% |
| 2015 FY | 2.86 Billion CNY | 30.97% |
| 2014 FY | 2.18 Billion CNY | 36.38% |
| 2014 Q3 | 537.45 Million CNY | 2.56% |
| 2014 Q1 | 392.42 Million CNY | -25.2% |
| 2014 Q4 | 731.77 Million CNY | 36.16% |
| 2014 Q2 | 524.04 Million CNY | 33.54% |
| 2013 FY | 1.6 Billion CNY | -7.77% |
| 2013 Q2 | 312.83 Million CNY | -6.77% |
| 2013 Q3 | 429.63 Million CNY | 37.34% |
| 2013 Q1 | 335.54 Million CNY | -4.01% |
| 2013 Q4 | 524.64 Million CNY | 22.11% |
| 2012 Q2 | 529.01 Million CNY | 2.43% |
| 2012 Q4 | 349.57 Million CNY | 2.01% |
| 2012 Q1 | 516.48 Million CNY | 13.64% |
| 2012 Q3 | 342.69 Million CNY | -35.22% |
| 2012 FY | 1.73 Billion CNY | -8.54% |
| 2011 FY | 1.89 Billion CNY | 32.6% |
| 2011 Q3 | 543.85 Million CNY | 0.0% |
| 2011 Q4 | 454.48 Million CNY | -16.43% |
| 2010 FY | 1.43 Billion CNY | 69.7% |
| 2009 FY | 844.37 Million CNY | 0.0% |